GlassScriptPhysician profile
Nick M Pham
NPI 1801082508
$3,371.43
in general payments reported to CMS, 2019-2025
27 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $48.82 · 2021: $12.00 · 2022: $30.84 · 2023: $209 · 2024: $660 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,024.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $728.29 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Gilead Sciences, INC. | $425.91 | 2024-2025 | Vemlidy |
| Pfizer INC. | $239.87 | 2019-2024 | |
| Lilly USA, LLC | $239.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $188.17 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $177.92 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $160.94 | 2024-2025 | Zoryve |
| Novo Nordisk INC | $150.67 | 2019-2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $133.96 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.29 | 2019 | |
| Abbvie INC. | $124.26 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.63 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $77.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $72.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.53 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $56.60 | 2019 | |
| Allergan, INC. | $51.16 | 2019 | |
| Amarin Pharma, INC. | $35.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.64 | 2019 | |
| Viiv Healthcare Company | $23.18 | 2024 | Apretude |
| Horizon Therapeutics Plc | $22.84 | 2019 | |
| Sumitomo Pharma America, INC. | $22.33 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $21.53 | 2024 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $18.31 | 2022 | |
| Genentech USA, INC. | $17.80 | 2019 | |
| Viatris Specialty LLC | $17.26 | 2025 | Yupelri |
| Abbott Laboratories | $16.27 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nick Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.